Skip to main content

Advertisement

Table 3 Congruency of treatment recommendations for skin infections in adults with national commensal S. aureus resistance rates

From: Primary care treatment guidelines for skin infections in Europe: congruence with antimicrobial resistance found in commensal Staphylococcus aureusin the community

  Topical AB Resistance rate* First choice systemic AB Resistance rate* Second choice systemic AB Resistance rate*
Impetigo
Austria Fusidic acid 1.0 Cephalosporin No data Amoxicillin + Clavulanic acid 1.5
Belgium Fusidic acid 3.4 Flucloxacillin 2.2 Clarithromycin 16.3
France Fusidic acid 4.0 No specific advice
Hungary No guideline
Netherlands Fusidic acid 5.2 Flucloxacillin 1.0 Azithromycin 6.9
Spain Mupirocin 1.6 Penicillin (IM)/Cloxacillin 86.0 Clindamycin 9.5
     1.3   
Sweden Retapamulin 0 Flucloxacillin 0 Cefadroxil No data
UK Fusidic acid 7.8 Flucloxacillin 1.6 Clarithromycin 8.9
Cellulitis
Austria    Penicillin (parenteral) 64.4 Clindamycin 11.1
Belgium    Flucloxacillin 2.2 Clindamycin 14.4
France No guideline
Hungary No guideline
Netherlands    Flucloxacillin 1.0 Claritromycin 5.5
Spain    Cloxacillin 1.3 Amoxicillin + Clavulanic acid 1.3
Sweden No guideline
UK    Flucloxacillin 1.6 Ery/Clarithromycin 8.9
Folliculitis and Furuncle
Austria    Cephalosporin No data Amoxicillin + Clavulanic acid 1.5
Belgium No guideline
France No guideline
Hungary No guideline
Netherlands    Flucloxacillin 1.0 No second choice
Spain    Cloxacillin 1.3 No second choice
Sweden    Flucloxacillin 0 Cefadroxil No data
UK    Flucloxacillin 1.6 Ery/Clarithromycin 8.9
  1. *A recommendation is congruent if the resistance rate in S. aureus to that antibiotic is <20%. Data in bold indicate a resistance rate of >20%.